E-LIB Suche - Ergebnisse für: Bendell, Johanna

1

Predictive potential of angiopoietin-2 in a mCRC subpopulat..:

Ferreira, Cláudia S. ; Babitzki, Galina ; Klaman, Irina...
Frontiers in Oncology. 13 (2023) - p. , 2023

2

First-in-human study of oleclumab, a potent, selective anti..:

Bendell, Johanna ; LoRusso, Patricia ; Overman, Michael...
Cancer Immunology, Immunotherapy. 72 (2023) 7 - p. 2443-2458 , 2023

Link: https://doi.org/10.1007/..

3

Napabucasin Plus FOLFIRI in Patients With Previously Treate..:

Shah, Manish A. ; Yoshino, Takayuki ; Tebbutt, Niall C....
Clinical Colorectal Cancer. 22 (2023) 1 - p. 100-110 , 2023

Link: https://doi.org/10.1016/..

4

Tumor-intrinsic expression of the autophagy gene Atg16l1 su..:

Taraborrelli, Lucia ; Şenbabaoğlu, Yasin ; Wang, Lifen...
Nature Communications. 14 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

5

Phase I/II sequencing study of azacitidine, epacadostat, an..:

Luke, Jason J. ; Fakih, Marwan ; Schneider, Charles...
British Journal of Cancer. 128 (2023) 12 - p. 2227-2235 , 2023

Link: https://doi.org/10.1038/..

6

Epacadostat Plus Pembrolizumab and Chemotherapy for Advance..:

Powderly, John D ; Klempner, Samuel J ; Naing, Aung...
The Oncologist. 27 (2022) 11 - p. 905-e848 , 2022

Link: https://doi.org/10.1093/..

7

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab ..:

Herbst, Roy S. ; Arkenau, Hendrik Tobias ; Bendell, Johanna...
Journal of Thoracic Oncology. 16 (2021) 2 - p. 289-298 , 2021

Link: https://doi.org/10.1016/..

8

CX-072 (pacmilimab), a Probody®PD-L1 inhibitor, in advanced..:

Naing, Aung ; Thistlethwaite, Fiona ; De Vries, Elisabeth G.E....
Journal for ImmunoTherapy of Cancer. 9 (2021) 7 - p. e002447 , 2021

Link: https://doi.org/10.1136/..

9

Pegilodecakin as monotherapy or in combination with anti‐PD..:

Tannir, Nizar M. ; Papadopoulos, Kyriakos P. ; Wong, Deborah J....
International Journal of Cancer. 149 (2021) 2 - p. 403-408 , 2021

Link: https://doi.org/10.1002/..

10

GB1275, a first-in-class CD11b modulator: rationale for imm..:

DeNardo, David G ; Galkin, Anna ; Dupont, Jakob..
Journal for ImmunoTherapy of Cancer. 9 (2021) 8 - p. e003005 , 2021

Link: https://doi.org/10.1136/..

11

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combinat..:

Sanborn, Rachel E ; Hamid, Omid ; de Vries, Elisabeth GE...
Journal for ImmunoTherapy of Cancer. 9 (2021) 7 - p. e002446 , 2021

Link: https://doi.org/10.1136/..

12

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mT..:

Zauderer, Marjorie G. ; Alley, Evan W. ; Bendell, Johanna...
Investigational New Drugs. 39 (2021) 4 - p. 1081-1088 , 2021

Link: https://doi.org/10.1007/..

13

Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcita..:

Bendell, Johanna ; Sharma, Sunil ; Patel, Manish R....
The Oncologist. 25 (2020) 11 - p. 954-962 , 2020

Link: https://doi.org/10.1634/..

14

Immunologic and tumor responses of pegilodecakin with 5-FU/..:

Hecht, J. Randolph ; Papadopoulos, Kyriakos P. ; Falchook, Gerald S....
Investigational New Drugs. 39 (2020) 1 - p. 182-192 , 2020

Link: https://doi.org/10.1007/..

15

Development and Preliminary Clinical Activity of PD-1-Guide..:

Berezhnoy, Alexey ; Sumrow, Bradley J. ; Stahl, Kurt...
Cell Reports Medicine. 1 (2020) 9 - p. 100163 , 2020

Link: https://doi.org/10.1016/..